This symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.
Monday, May 1, 2017
12:45 PM – 1:00 PM
CME Symposium / Q&A Session
1:00 PM – 2:15 PM
McCormick Place - South Building
2301 S. King Drive
Chicago, IL 60616
|12:45 PM – 1:00 PM
|1:00 PM – 1:05 PM
||Welcome and Introductions
||Nassim Kamar, MD, PhD
|1:05 PM – 1:30 PM
||AMR: Transplant Glomerulopathy and Emerging Therapies
||Robert A. Montgomery, MD, DPhil, FACS
|1:30 PM – 1:55 PM
||CMV: Overcoming Therapeutic Limitations with Emerging Therapies
||Camille Nelson Kotton, MD, FIDSA, FAST
|1:55 PM – 2:15 PM
||Interactive Panel Discussion/Audience Q&A (Clinical Cases and Current Issues in AMR and CMV Management)
Nassim Kamar, MD, PhD (Chair)
Head of the Department of Nephrology and Organ Transplantation
Toulouse University Hospital
Toulouse, France (Europe)
Robert A. Montgomery, MD, DPhil, FACS
Professor of Surgery
Director, NYU Langone Transplant Institute
New York, New York (USA)
Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director,Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Past Chair, Infectious Disease Community of Practice, American Society of Transplantation
Boston, Massachusetts (USA)
This activity has been designed to meet the educational needs of clinicians and pharmacists who manage cytomegalovirus (CMV) infection and/or antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).
STATEMENT OF NEED
Two key issues affecting solid organ transplant (SOT) are antibody-mediated rejection (AMR) and opportunistic infections, including cytomegalovirus (CMV). Strategies to prevent and/or manage these complications are being extensively researched and the field is rapidly evolving.
Current evidence indicates that AMR is a major underlying cause
of allograft rejection. Research has identified a relationship
between the development of AMR and the presence of circulating
donor-specific antibodies (DSAs).1,2 Given that an estimated
30% of patients waiting for transplant have high levels of
circulating DSAs, the potential risk for AMR is high. Because AMR
is a complement-mediated process, therapies directed at the
complement system may offer promise as potential treatments.
Cytomegalovirus (CMV) infections are the most prevalent
infections in patients receiving SOT, and CMV disease is an
important cause of morbidity and mortality in these patients.3,4 CMV increases mortality risk independently of other mortality risk
factors5, and it may cause organ damage even in the absence of obvious CMV disease.6 New therapies with novel mechanisms of action and better tolerability profiles are under investigation in clinical trials.
1. Willicombe M, Roufosee, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome. Transplantation. 2011;92(2):176-182.
2. Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014;34(7):733-744.
3. Kasiske BL, Zeier MG, Craig JC, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-155.
4. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6(12):711-721.
5. Sagedal S, Rollag H, Hartmann A, et al. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk.
Clin Transplant. 2007;21(3):309-313.
6. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8(5):975-983.
After completing this activity, the participant should be better able to:
- Incorporate evidence-based treatment protocols and select appropriate therapeutic agents to prevent and treat AMR based on pathophysiology
- Outline the significant contribution of human leukocyte antigen (HLA) antibodies and complement deposition in transplant glomerulopathy (TG) and graft loss
- Describe the limitations of current CMV preventive and treatment strategies for SOT
- Integrate existing and future antivirals into the treatment of CMV infection and/or disease in SOT
PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 0809-9999-17-372-L01-P)
Type of Activity:Knowledge
For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from CEcertificate@pimed.com within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
There is no fee for this educational activity.
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact RMEI Medical Education, LLC prior to the live event at 866-770-RMEI.
Additional educational activities offered by RMEI Medical Education, LLC can be found at www.RMEI.com or by calling toll free 866-770-RMEI.